Study of AZD0754 in Participants With Metastatic Prostate Cancer

Required: STEAP2 expression (testing required; no eligibility threshold specified)

Consent and provision of tumour material to assess STEAP2 expression and other correlative biomarkers retrospectively with pre- and post-treatment biopsies

Allowed: BRCA1 pathogenic mutation

For participants with pathogenic mutations in BRCA1 or BRCA2, they must also have received a PARP-inhibitor or be intolerant of this therapy

Allowed: BRCA2 pathogenic mutation

For participants with pathogenic mutations in BRCA1 or BRCA2, they must also have received a PARP-inhibitor or be intolerant of this therapy

Must have received: novel hormonal agent (abiraterone, enzalutamide, apalutamide, darolutamide)

Participant has previously received a NHA (ie, abiraterone, enzalutamide, apalutamide, darolutamide)

Must have received: taxane

Participant has previously received...a taxane as part of their treatment for prostate cancer

Cannot have received: CAR-T cell therapy

Prior treatment with a CAR-T therapy directed at any target

Cannot have received: STEAP2-targeted therapy

any therapy that is targeted to STEAP2